GlassScriptPhysician profile
Ashleigh Farris
NPI 1285015883
$2,414.87
in general payments reported to CMS, 2019-2025
21 companies · $440 in 2025
The $440 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $583 · 2022: $707 · 2023: $358 · 2024: $328 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,125.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $616.58 | 2021-2025 | Wegovy, Ozempic |
| Abbvie INC. | $469.42 | 2021-2025 | |
| Lilly USA, LLC | $236.87 | 2021-2025 | Zepbound, Jardiance, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $198.95 | 2022-2023 | |
| Pfizer INC. | $189.11 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $153.90 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $81.71 | 2021-2025 | Airsupra, Farxiga |
| Astellas Pharma US INC | $76.05 | 2023-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $72.78 | 2021-2025 | Bexsero, Penmenvy, Shingrix |
| Amgen INC. | $43.79 | 2025 | Evenity |
| Exact Sciences Corporation | $39.55 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $34.32 | 2021 | |
| Nestle Healthcare Nutrition INC. | $33.26 | 2021 | |
| Novartis Pharmaceuticals Corporation | $27.77 | 2023 | |
| Allergan, INC. | $23.89 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $23.81 | 2023 | Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.17 | 2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.15 | 2022 | |
| Acadia Pharmaceuticals INC | $19.08 | 2024 | Daybue |
| Janssen Pharmaceuticals, INC | $16.62 | 2021 | |
| Philips North America LLC | $14.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashleigh Farris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.